# Geneoscopy

> Geneoscopy is a St. Louis life-sciences company building noninvasive diagnostics that read RNA biomarkers in stool to prevent, detect, and treat gastrointestinal disease. Its flagship product, ColoSense, is the first FDA-approved multi-target stool RNA (mt-sRNA) test for colorectal cancer screening in adults 45 and older, designed to lift screening compliance by replacing the colonoscopy prep and the clinic visit with a kit that arrives in the mail. Founded by siblings Andrew and Erica Barnell, the company is extending its RNA platform from cancer screening into inflammatory bowel disease.

- **Founded:** 2015
- **Headquarters:** St. Louis, Missouri, United States
- **Founders:** Andrew Barnell (Co-Founder & CEO), Erica Barnell (Co-Founder & Chief Medical and Science Officer), Yiming Kang (Co-Founder (data analysis / computational biology))
- **Team size:** ~61 employees
- **Products:** ColoSense, RNA biomarker platform, IBD pipeline / companion diagnostics
- **Notable:** ColoSense received FDA approval as the first multi-target stool RNA test for colorectal cancer screening, FDA Breakthrough Device designation for ColoSense, CRC-PREVENT pivotal trial: 93% sensitivity for colorectal cancer, 45% sensitivity for advanced adenomas

## Products & services

- **ColoSense** — The first FDA-approved multi-target stool RNA (mt-sRNA) test for colorectal cancer screening in adults aged 45 and older. Combines Geneoscopy's proprietary RNA-from-stool isolation platform with Bio-Rad Droplet Digital PCR; reported 93% sensitivity for colorectal cancer and 45% sensitivity for advanced adenomas in the CRC-PREVENT pivotal trial. An at-home kit, no prep or dietary changes required.
- **RNA biomarker platform** — A proprietary methodology for isolating human RNA from stool samples, enabling a dynamic view of disease activity rather than a static snapshot - the foundation for the company's broader GI diagnostics pipeline.
- **IBD pipeline / companion diagnostics** — Pipeline programs applying the stool-RNA platform to inflammatory bowel disease and GI disease companion diagnostics for precision-medicine partnerships.

## Achievements

- ColoSense received FDA approval as the first multi-target stool RNA test for colorectal cancer screening
- FDA Breakthrough Device designation for ColoSense
- CRC-PREVENT pivotal trial: 93% sensitivity for colorectal cancer, 45% sensitivity for advanced adenomas
- Closed $105M Series C in January 2025 led by Bio-Rad
- Total funding of approximately $217.9M
- ColoSense included as a preferred option in the American Cancer Society colorectal cancer screening guidelines
- CMS granted Medicare coverage for ColoSense (June 2026), reaching ~65M beneficiaries
- Won the WashU Skandalaris Fire Award as a university startup

## Latest updates

- **2026-06** — CMS granted Medicare coverage for ColoSense under the National Coverage Determination for colorectal cancer screening, opening access to roughly 65 million beneficiaries.
- **2025-01** — Closed $105M Series C funding round led by Bio-Rad Laboratories to power the launch of ColoSense and the next generation of GI diagnostics.
- **2024** — Prepared the commercial launch of FDA-approved ColoSense, including a Labcorp collaboration for broad availability.
- **2024** — ColoSense included as a preferred option in the American Cancer Society colorectal cancer screening guidelines update.

## Links

- Website: https://geneoscopy.com
- LinkedIn: http://www.linkedin.com/company/geneoscopy
- Twitter/X: https://twitter.com/GeneoscopyCo
- Facebook: https://facebook.com/GeneoscopyCo

---

Profile page: https://yespress.io/geneoscopy
Published by YesPress — https://yespress.io
Last updated: 2026-06-15